Arrowhead forms JV with Vivo Capital for Greater China; licenses four RNAi cardiometabolic drugs

ARROWHEAD PHARMACEUTICALS, INC.

Vivo Capital provided $60M initial funding to Visirna Therapeutics, JV in which Arrowhead holds majority stake.
Visirna gets exclusive rights to develop and commercialize four investigational RNAi therapeutics in Greater China.
Arrowhead eligible to receive royalties on net commercial sales in the licensed territory.
Vivo Capital's Hongbo Lu and Gaurav Aggarwal to join Visirna board; Arrowhead also appoints board members.
Visirna to be headquartered in Shanghai; recruitment of management and staff underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.